Evolving Understanding of Biomarkers of Response to Immune Checkpoint Inhibition in NSCLC

Download this slideset for expert insights on the role of biomarkers in the optimal use of immunotherapy in the care of patients with NSCLC.
Leora Horn, MD, MSc, FRCPC
Edward S. Kim, MD, FACP, FASCO
Format: Microsoft PowerPoint (.ppt)
File Size: 2.84 MB
Released: June 25, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Safety and response data from phase Ib TROPION-Lung02 study of Dato-DXd plus pembrolizumab with or without platinum chemotherapy in advanced NSCLC, presented at WCLC 2022 reported by Clinical Care Options (CCO)

Released: August 18, 2022

Results from the HUDSON umbrella trial of novel durvalumab combination regimens in patients with advanced NSCLC who failed previous immunotherapy treatment, presented at WCLC 2022 and reported by Clinical Care Options (CCO)

Released: August 18, 2022

Initial PFS and OS results from phase II NADIM II study of neoadjuvant nivolumab plus CT vs CT alone in patients with resectable stage IIIA-B NSCLC, presented at WCLC 2022 and reported by Clinical Care Options (CCO)

Released: August 18, 2022

Evaluation of YESS study adding personalized smoking cessation support to a lung cancer screening program, presented at WCLC 2022 and reported by Clinical Care Options (CCO)

Released: August 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings